Table 1.

Table Compounds/drugs Panel used for experimentation.

Compound	Simplified Group Identification	Family/Chemical Group	Activity	References
BS-1-28	BS	MMB (Melampomagnolide b) indole esters	NFk-B inhibitors	[27]
BS-2-04	BS	MMB indole esters	NFk-B inhibitors	[27]
BS-4-60	BS	MMB indole esters	NFk-B inhibitors	[27]
BSK-1-97	BSK	MMB-Thiadiazolidinone	NFk-B and GSK-3 B inhibitors	Non-published
BSK-2-17	BSK	MMB-Thiadiazolidinone	NFk-B and GSK-3 B inhibitors	Non-published
BSK-2-26	BSK	MMB-Thiadiazolidinone	NFk-B and GSK-3 B inhibitors	Non-published
JVM-3-55	JVM	MMB dimers	NFk-B inhibitors	[28]
JVM-3-62	JVM	MMB dimers	NFk-B inhibitors	[28]
JVM-4-25	JVM	MMB Triazole dimers	NFk-B inhibitors	[29]
JVM-4-26	JVM	MMB Triazole dimers	NFk-B inhibitors	[29]
PNR-4-44	PNR	Heterocyclic trans-cyanocombretastatin analogues	Tubulin inhibitors	[32]
PNR-4-48	PNR	Heterocyclic trans-cyanocombretastatin analogues	Tubulin inhibitors	[32]
PNR-5-02	PNR	CA-4 triazole	Tubulin inhibitors	[31]
PNR-5-82	PNR	Indole barbiturate and thiobarbiturates	COX-2 inhibitors	[30]
PNR-5-85	PNR	Indole barbiturate and thiobarbiturates	COX-2 inhibitors	[30]
PNR-5-88	PNR	Indole barbiturate and thiobarbiturates	COX-2 inhibitors	[30]
PNR-7-74	PNR	Heterocyclic trans-cyanocombretastatin	Tubulin inhibitors	[32]
PNR-7-84	PNR	Heterocyclic trans-cyanocombretastatin	Tubulin inhibitors	[32]
ST-145	ST	Resveratrol analogues	Tubulin inhibitors	[33]
ST-145(B)	ST	Novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin	Tubulin inhibitors	[34]
ST-148	ST	Resveratrol analogues	Tubulin inhibitors	[33]
ST-467	ST	Novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin	Tubulin inhibitors	[34]